Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC):: An interim safety analysis of the GEICAM 9805 study.

被引：0
|
作者：
Martin, M [1 ]
Lluch, A [1 ]
Seguí, MA [1 ]
Antón, A [1 ]
Ruiz, A [1 ]
Ramos, M [1 ]
Rodríguez-Lescure, A [1 ]
Adrover, E [1 ]
机构：
[1] Spanish Breast Canc Res Grp, GEICAM, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
620
引用
收藏
页码：32S / 32S
页数：1
相关论文
共 48 条
  • [1] Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide):: Impact of adding prophylactic growth factors (GF) to TAC.: GEICAM Study 9805.
    Martin, M
    Lluch, A
    Seguí, MA
    Antón, A
    Fernández-Chacón, C
    Ruíz, A
    Ramos, M
    Adrover, E
    Rodríguez-Lescure, A
    Casado, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 29S - 29S
  • [2] Prophylactic pegfilgrastim support with adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) in node-positive breast cancer patients
    Rifa, Juli
    Del Alba, A. Gonzalez
    Perello, A.
    Alarcon, J.
    Avella, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 112 - 112
  • [3] TAC VERSUS FAC AS ADJUVANT CHEMOTHERAPY FOR HIGH-RISK NODE-NEGATIVE BREAST CANCER: RESULTS OF THE GEICAM 9805 TRIAL
    Martin, M.
    Lluch, A.
    Segui, M. A.
    Ruiz, A.
    Ramos, M.
    Adrover, E.
    Rodriguez-Lescure, A.
    Grosse, R.
    Calvo, L.
    Anton, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 77 - 77
  • [4] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [5] Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial
    Martin, M.
    Iluch, A.
    Segui, M.
    Ruiz, A.
    Ramos, M.
    Adrover Cebrian, E.
    Rodriguez-Lescure, A.
    Grosse, R.
    Calvo Martinez, L.
    Anton, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
  • [7] The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001.
    Vogel, CL
    Mackey, JR
    Martin, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 46S - 46S
  • [8] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [9] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
  • [10] A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Rapoport, B. L.
    Moodley, S. D.
    Jacobs, C.
    Pienaar, R.
    Fourie, S.
    Szpak, W. M.
    [J]. BREAST, 2007, 16 : S64 - S64
12345